Highlights IntelGenx Technologies Corp.

Equities

IGXT

US45822R1014

Market Closed - OTC Markets Other stock markets 14:38:44 2024-05-15 EDT			5-day change	1st Jan Change
0.1735 ^USD	+5.79%		+11.15%	+25.63%

04-08	Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	CI
04-05	IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	04-08	CI
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	04-05	MT
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA	04-05	CI
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises	03-21	MT
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share, at an Offering Price of $10.00 Each, For a Max Offering amount of $20 Million	02-20	MT
IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx?s VetaFilm® Platform in Healthy Dogs and Cats	02-05	CI
IntelGenx, Covenant Animal Health Partners Unit Sign Development, License Pacts for VetaFilm	12-18	MT
IntelGenx Corp. Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm	12-18	CI
IntelGenx Brief: Announcing New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm	12-18	MT
IntelGenx Announcing Shareholder Approval of Financing Transactions	11-28	MT
IntelGenx Receives OK to Conduct Montelukast VersaFilm Phase 2 Clinical Trial in Patients with Parkinson's Disease	11-14	MT
IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's Disease	11-14	CI
IntelGenx Technologies Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
IntelGenx Announced Co-development and Commercialization of Cannabinoid-Infused VersaFilm Products with Tilray	11-06	MT
IntelGenx Brief: Announciing Co-development and Commercialization of Cannabinoid-Infused VersaFilm Products with Tilray	11-06	MT
Intelgenx Technologies Corp. Announces Co-Development and Commercialization of Cannabinoid-Infused Versafilm® Products with Tilray	11-06	CI
Gensco® Pharma and Intelgenx Announces Rizafilm Commercialization Update in the United States	23-09-26	CI
IntelGenx Provides Rizafilm U.S. Commercialization Update; Receives First Purchase Order From Gensco Pharma	23-09-21	MT
IntelGenx Brief: Provides RIZAFILM U.S. Commercialization Update; Receives first purchase order from Gensco Pharma	23-09-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights IntelGenx Technologies Corp.

Equities

IGXT

US45822R1014

Highlights

Filters